Pharma-bio Serv, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
OQB
Pharma-Bio Serv, Inc. filed an amendment to its 2025 annual report to update information on directors, executive compensation, security ownership, related party transactions, and principal accountant fees.
OQB
Pharma-Bio Serv, Inc. reported a significantly reduced net loss of $0.1 million for fiscal year 2025, driven by strong European market growth and improved gross profit margins, despite an overall revenue decline.
OQB
Pharma-Bio Serv, Inc. files an amendment to its annual report on Form 10-K to include information required by Items 10 through 14 of Part III, focusing on directors, executive compensation, security ownership, related transactions, and principal accountant fees.
OQB
Pharma-Bio Serv's fiscal year 2024 saw a significant revenue decrease due to project declines in key markets, resulting in a net loss.
OQB
Pharma-Bio Serv, Inc. has filed an amendment to its annual report on Form 10-K to include required information regarding directors, executive compensation, and other corporate governance matters.
OQB
10-K: Pharma-Bio Serv Reports Fiscal Year 2023 Results, Revenue Declines Offset by Improved Profitability
Pharma-Bio Serv's annual report reveals a decrease in revenue for fiscal year 2023, but an increase in net income due to improved gross profit margins and other income.